Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Comparison of Three Different A1 Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs

John A. Auchampach, Xiaowei Jin, Jeannine Moore, Tina C. Wan, Laura M. Kreckler, Zhi-Dong Ge, Jayashree Narayanan, Eric Whalley, William Kiesman, Barry Ticho, Glenn Smits and Garrett J. Gross
Journal of Pharmacology and Experimental Therapeutics March 2004, 308 (3) 846-856; DOI: https://doi.org/10.1124/jpet.103.057943
John A. Auchampach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaowei Jin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeannine Moore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tina C. Wan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura M. Kreckler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhi-Dong Ge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jayashree Narayanan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Whalley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Kiesman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry Ticho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glenn Smits
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Garrett J. Gross
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A1 adenosine receptor (AR) antagonists are effective diuretic agents that may be useful for treating fluid retention disorders including congestive heart failure. However, antagonism of A1ARs is potentially a concern when using these agents in patients with ischemic heart disease. To address this concern, the present study was designed to compare the actions of the A1AR antagonists CPX (1,3-dipropyl-8-cyclopentylxanthine), BG 9719 (1,3-dipropyl-8-[2-(5,6-epoxynorbornyl)]xanthine), and BG 9928 (1,3-dipropyl-8-[1-(4-propionate)-bicyclo-[2,2,2]octyl]xanthine) on acute myocardial ischemia/reperfusion injury and ischemic preconditioning (IPC) in an in vivo dog model of infarction. Barbital-anesthetized dogs were subjected to 60 min of left anterior descending coronary artery occlusion followed by 3 h of reperfusion, after which infarct size was assessed by staining with triphenyltetrazolium chloride. IPC was elicited by four 5-min occlusion/5-min reperfusion cycles produced 10 min before the 60-min occlusion. Multiple-cycle IPC produced a robust reduction (∼65%) in infarct size; this effect of IPC on infarct size was not abrogated in dogs pretreated with any of the three AR antagonists. Surprisingly, in the absence of IPC, pretreatment with CPX or BG 9928 before occlusion or immediately before reperfusion resulted in significant reductions (∼40–50%) in myocardial infarct size. However, treatment with an equivalent dose of BG 9719 had no similar effect. We conclude that the A1AR antagonists BG 9719, BG 9928, and CPX do not exacerbate cardiac injury and do not interfere with IPC induced by multiple ischemia/reperfusion cycles. We discuss the possibility that the cardioprotective actions of CPX and BG 9928 may be related to antagonism of A2BARs.

Footnotes

  • This work was supported by National Institutes of Health Grants R01 HL60051, R01 HL08311, and T32 HL07792, by American Heart Association Research Fellowships 0320019Z and 0315274Z, and by a research grant from Biogen, Inc. (Cambridge, MA).

  • DOI: 10.1124/jpet.103.057943.

  • ABBREVIATIONS: AR, adenosine receptor; CPX, 1,3-dipropyl-8-cyclopentylxanthine; BG 9719, 1,3-dipropyl-8-[2-(5,6-epoxynorbornyl)]xanthine; BG 9928, 1,3-dipropyl-8-[1-(4-propionate)-bicyclo-[2,2,2]octyl]xanthine; IPC, ischemic preconditioning; GFR, glomerular filtration rate; G418, geneticin; [125I]ZM 241385, 4-(2-[7-amino-2-(2-furyl)[1,2,4]-triazolo[2,3-a][1,3,5]triazin-5-yl amino]ethyl)-3-[125I]iodophenol; [125I]AB-MECA, N6-(4-amino-3-[125I]iodobenzyl)adenosine-5′-N-methylcarboxamide; [3H]MRS 1754, 1,3-dipropyl-8-[4-[((4-cyano-[2,6-3H]phenyl)carbamoylmethyl)oxy-]phenyl]xanthine; NECA, adenosine-5′-N-ethylcarboxamide; LAD, left anterior descending; DPSPX, 1,3-dipropyl-8-sulfophenylxanthine; CCPA, 2-chloro-N6-cyclopentyladenosine; CGS 21680, 2-[p-(2-carboxyethyl)phenethylamino]-5′-N-ethylcarboxamidoadenosine; Precond, preconditioning.

    • Received August 22, 2003.
    • Accepted November 5, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 308 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 308, Issue 3
1 Mar 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of Three Different A1 Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Comparison of Three Different A1 Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs

John A. Auchampach, Xiaowei Jin, Jeannine Moore, Tina C. Wan, Laura M. Kreckler, Zhi-Dong Ge, Jayashree Narayanan, Eric Whalley, William Kiesman, Barry Ticho, Glenn Smits and Garrett J. Gross
Journal of Pharmacology and Experimental Therapeutics March 1, 2004, 308 (3) 846-856; DOI: https://doi.org/10.1124/jpet.103.057943

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleCARDIOVASCULAR

Comparison of Three Different A1 Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs

John A. Auchampach, Xiaowei Jin, Jeannine Moore, Tina C. Wan, Laura M. Kreckler, Zhi-Dong Ge, Jayashree Narayanan, Eric Whalley, William Kiesman, Barry Ticho, Glenn Smits and Garrett J. Gross
Journal of Pharmacology and Experimental Therapeutics March 1, 2004, 308 (3) 846-856; DOI: https://doi.org/10.1124/jpet.103.057943
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Anti-apoptotic effect of rosuvastatin via autophagy
  • Improved Assessment of Cardiovascular Safety Data
  • G6PD, DNA methylation, and PAH
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics